Pregled bibliografske jedinice broj: 1238422
Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti- SARS-CoV-2 antibodies
Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti- SARS-CoV-2 antibodies // Nature communications, 13 (2022), 1; 3716, 9 doi:10.1038/s41467-022-31300-9 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1238422 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Homogeneous surrogate virus neutralization assay
to rapidly assess neutralization activity of anti-
SARS-CoV-2 antibodies
Autori
Kim, Sun Jin ; Yao, Zhong ; Marsh, Morgan C. ; Eckert, Debra M. ; Kay, Michael S. ; Lyakisheva, Anna ; Pasic, Maria ; Bansal, Aiyush ; Birnboim, Chaim ; Jha, Prabhat ; Galipeau, Yannick ; Langlois, Marc-Andre ; Delgado, Julio C. ; Elgort, Marc G. ; Campbell, Robert A. ; Middleton, Elizabeth A. ; Štagljar, Igor ; Owen, Shawn C.
Izvornik
Nature communications (2041-1723) 13
(2022), 1;
3716, 9
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
SPIKE PROTEIN ; BINDING ; IMMUNOASSAY ; SARS-COV-2 ; INHIBITION
Sažetak
The COVID-19 pandemic triggered the development of numerous diagnostic tools to monitor infection and to determine immune response. Although assays to measure binding antibodies against SARS-CoV-2 are widely available, more specific tests measuring neutralization activities of antibodies are immediately needed to quantify the extent and duration of protection that results from infection or vaccination. We previously developed a ‘Serological Assay based on a Tri-part split-NanoLuc® (SATiN)’ to detect antibodies that bind to the spike (S) protein of SARS-CoV-2. Here, we expand on our previous work and describe a reconfigured version of the SATiN assay, called Neutralization SATiN (Neu-SATiN), which measures neutralization activity of antibodies directly from convalescent or vaccinated sera. The results obtained with our assay and other neutralization assays are comparable but with significantly shorter preparation and run time for Neu-SATiN. As the assay is modular, we further demonstrate that Neu-SATiN enables rapid assessment of the effectiveness of vaccines and level of protection against existing SARS-CoV-2 variants of concern and can therefore be readily adapted for emerging variants.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
- Nature Index